Target type: biologicalprocess
The process in which an angiotensin-mediated signaling system present in the brain regulates the force with which blood passes through the circulatory system. [PMID:2909574]
The brain renin-angiotensin system (RAS) is a complex and crucial system that plays a vital role in regulating various physiological processes within the central nervous system. Unlike the peripheral RAS, which primarily focuses on blood pressure regulation, the brain RAS exerts its influence on a wider range of functions, including thirst, salt appetite, blood pressure, stress response, and cognitive processes.
The brain RAS is characterized by the presence of all the components necessary for the synthesis and degradation of angiotensin II (Ang II), the primary effector of the system. These components include renin, angiotensinogen, angiotensin-converting enzyme (ACE), and angiotensin-converting enzyme 2 (ACE2).
Renin, a proteolytic enzyme, is produced by neurons in specific regions of the brain, including the subfornical organ, the circumventricular organs, and the hypothalamus. Its release is triggered by various stimuli, such as dehydration, sodium depletion, and stress. Renin cleaves angiotensinogen, a precursor protein produced in the liver, to generate angiotensin I (Ang I).
Ang I is then converted to the active peptide Ang II by ACE, an enzyme primarily localized in the endothelium of blood vessels. ACE is also expressed in the brain, primarily in the circumventricular organs and the hypothalamus. Ang II acts as the main effector of the brain RAS, binding to specific receptors located on neurons and glial cells.
The brain RAS also involves the action of ACE2, an enzyme that competes with ACE for Ang I as a substrate. ACE2 converts Ang I to Ang 1-7, a peptide with opposing actions to Ang II. Ang 1-7 binds to the Mas receptor, activating signaling pathways that counteract the effects of Ang II.
The brain RAS exerts its effects through multiple mechanisms, including:
- Direct action on neurons: Ang II binds to Ang II receptors (AT1 and AT2) on neurons, triggering various signaling pathways that regulate neuronal activity and neurotransmitter release.
- Modulation of neurotransmitter release: Ang II influences the release of various neurotransmitters, including dopamine, norepinephrine, serotonin, and glutamate, playing a role in regulating mood, cognition, and behavior.
- Regulation of blood-brain barrier permeability: Ang II can alter the permeability of the blood-brain barrier, influencing the transport of nutrients, hormones, and drugs across the barrier.
- Control of thirst and salt appetite: Ang II stimulates thirst and salt appetite, helping to maintain fluid and electrolyte balance.
- Integration with other brain systems: The brain RAS interacts with other brain systems, including the hypothalamic-pituitary-adrenal axis, the autonomic nervous system, and the immune system, contributing to the regulation of stress response, blood pressure, and inflammation.
The brain RAS is implicated in various physiological and pathological conditions, including:
- Hypertension: Ang II plays a crucial role in the development and maintenance of hypertension, both centrally and peripherally.
- Cardiovascular disease: The brain RAS contributes to cardiovascular disease by influencing heart rate, blood pressure, and vascular tone.
- Stroke: Ang II has been shown to exacerbate stroke damage by promoting inflammation and neuronal cell death.
- Alzheimer's disease: The brain RAS is implicated in the pathogenesis of Alzheimer's disease, contributing to cognitive decline and neuronal dysfunction.
- Depression: The brain RAS is involved in the regulation of mood and stress response, and alterations in its activity have been linked to depression.
The brain RAS is a complex and fascinating system that continues to be actively researched. Understanding its intricate mechanisms and roles in various physiological and pathological processes will provide valuable insights into the development of novel therapeutic strategies for a wide range of diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Type-2 angiotensin II receptor | An angiotensin II receptor 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P50052] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
5-iodo-2-(oxaloamino)benzoic acid | organoiodine compound | ||
candesartan | candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. candesartan: a nonpeptide angiotensin II receptor antagonist | benzimidazolecarboxylic acid; biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
avapro | irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. | azaspiro compound; biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
losartan | losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist |
miconazole | 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion. | dichlorobenzene; ether; imidazoles | |
ipsapirone | N-arylpiperazine | ||
flesinoxan | |||
valsartan | valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity. Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. | biphenylyltetrazole; monocarboxylic acid; monocarboxylic acid amide | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
telmisartan | telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension. Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION. | benzimidazoles; biphenyls; carboxybiphenyl | angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic |
bexarotene | benzoic acids; naphthalenes; retinoid | antineoplastic agent | |
exp7711 | EXP7711: to search, use E#P7711(nm); angiotensin II receptor antagonist; structure given in first source | ||
bibs 39 | BIBS 39: structure given in first source; angiotensin II receptor antagonist | ||
a 81988 | A 81988: angiotensin II antagonist selective for type 1 receptors | ||
bibs 222 | BIBS 222: structure given in first source; angiotensin II receptor antagonist | ||
chrysamine g | chrysamine G: structure given in first source; RN refers to disodium salt | ||
angiotensin ii | Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V). | amino acid zwitterion; angiotensin II | human metabolite |
l 158809 | L 158809: RN & structure given in first source; angiotensin receptor antagonist | ||
2-(oxaloamino)benzoic acid | (oxaloamino)benzoic acid | ||
alitretinoin | Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. | retinoic acid | antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist |
tak 013 | |||
pd 123319 | PD123319 : An imidazopyridine consisting of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine having 4-(dimethylamino)-3-methylbenzyl, diphenylacetyl and carboxy and groups at positions 1, 5 and 6 respectively | imidazopyridine | angiotensin receptor antagonist; endothelin receptor antagonist; vasoconstrictor agent |
exp 655 | |||
saralasin | Saralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. | oligopeptide | |
l 162313 | L 162313: a biphenylimidazole derivative; a non-peptide angiotensin agonist; no further information available 2/95 | ||
l 163491 | L 163491: structure given in first source | ||
nrx 194204 | IRX4204: retinoid X receptor (RXR) agonist; structure in first source | ||
agn 194204 | AGN 194204: a retinoid X receptor ligand; structure in first source | ||
ema401 | |||
naluzotan | naluzotan: an antidepressant and anti-anxiety agent; structure in first source |